Avis Budget Group (NASDAQ:CAR | CAR Price Prediction) shares are up 13% in early trading Wednesday, continuing a rally that has now become one of the more extraordinary moves in recent market memory.
On April 21, 2026, Avis Budget Group Inc (CAR) shares rose 17.3% today, trading at $713.97. This surge comes after a remarkable performance over the past year,
Eli Lilly and Co (NYSE:LLY)'s acquisition of Kelonia Therapeutics is being seen as a positive step for long-term pipeline building, even as the target's lead assets remain in early clinical development, according to UBS analysts. The $3.25 billion deal, announced on Monday, is among the largest to date in the in vivo CAR-T space.
Meme stock mania is alive and well in April 2026. Avis Budget Group (NASDAQ:CAR) is leading the pack, but several other heavily-shorted stocks are joining in.
The wild trading in Avis Budget Group CAR +7.28% stock continued on Tuesday as shares of the rental-car company gained another 14% and have risen more than six-fold over the past month—and it could result in a regulatory inquiry.
Avis Budget Group, Inc. (NASDAQ:CAR) shares have gained more than 500% in less than a month. They now appear to be in a short-squeeze.
Shares of car rental company Avis Budget hit a record high on Tuesday, having quadrupled so far in April, as analysts pointed to a short squeeze that has dealt steep losses to investors betting against the stock.
Avis Budget Group (NASDAQ:CAR) stock is up 11% midday Monday, climbing from $493.86 to $550 as short-sellers scramble to cover positions they can no longer afford to hold.
Avis Budget (CAR) stock has surged by almost 390% over the last month and rose by almost 10% in Friday's trading, driven by a powerful short squeeze.
Avis's stock could still rally a lot more because of a technical “short squeeze” triggered in late March, according to Deutsche Bank.
Car rental stocks surged on Thursday after Hertz (HTZ) reported a significant increase in website traffic as travelers look for alternatives to flying amid a TSA shortage.
Lyell Immunopharma is a CAR-T developer with a single pivotal asset, ronde-cel, targeting LBCL and showing superior early efficacy and safety data. Ronde-cel's 93% ORR, 76% CR, and ~18-month mPFS in 3L+ LBCL patients outperformed approved peers, supporting a $1B+ peak sales opportunity. Valuation estimates suggest LYEL equity value of ~$45–55 per share, with the current price reflecting moderate success probability; pivotal data in 2027 is key.